Citius Oncology (CTOR) Change in Account Payables (2023 - 2026)

Citius Oncology's Change in Account Payables history runs 4 years deep, the most recent figure standing at -$1.6 million for Q1 2026.

• In Q1 2026, Change in Account Payables fell 194.36% year-over-year to -$1.6 million; the TTM figure through Mar 2026 stood at $1.2 million (down 91.75% YoY), while the FY2025 annual figure was $9.5 million, down 33.27% from the prior year.
• Change in Account Payables was -$1.6 million for Q1 2026 at Citius Oncology, up from -$2.8 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $11.4 million in Q2 2024 to a low of -$2.8 million in Q4 2025.
• Historically, Change in Account Payables has averaged $1.6 million across 4 years, with a median of $1.7 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Change in Account Payables jumped 312.87% in 2024, then slumped 220.81% in 2025.
• A 4-year view of Change in Account Payables shows it stood at -$1.1 million in 2023, then surged by 312.87% to $2.3 million in 2024, then plunged by 220.81% to -$2.8 million in 2025, then surged by 43.91% to -$1.6 million in 2026.
• The last three Change in Account Payables figures came in at -$1.6 million (Q1 2026), -$2.8 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.